Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, Ziping T. Li, Lingzhi Hong, Natalie Vokes, Yasir Y. Elamin, Celyne Bueno Hume, Ferdinandos Skoulidis, Carl M. Gay, George Blumenschein, Frank V. Fossella, Anne Tsao, Jianjun Zhang, Niki Karachaliou, Aurora O'Brate, Claudia Nanette Gann, Jeff Lewis, Waree Rinsurongkawong, J. Jack LeeDon Lynn Gibbons, Ara A. Vaporciyan, John V. Heymach, Mehmet Altan, Xiuning Le

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC'. Together they form a unique fingerprint.

Medicine & Life Sciences